Can new trial data pull the microbiome industry out of the shadows?

Can new trial data pull the microbiome industry out of the shadows?

STAT Plus: Microbiome-based drug makers are hoping new late-stage data will pull the field out of the shadows

By KATE SHERIDAN

ALEX HOGAN/STAT

The data will thrust the microbiome industry into the spotlight, its first since a high-profile clinical failure in 2016 threw a shadow over the field.

READ MORE